U.S. watchdog lifts price estimate for Bluebird, Vertex/CRISPR gene therapies to $2.1 million

U.S. watchdog lifts price estimate for Bluebird, Vertex/CRISPR gene therapies to $2.1 million

Submitted by admin on July 14, 2023 - 10:07am
Source: 
Reuters
News Tags: 
ICER
gene therapy
Vertex Pharmaceuticals
CRISPR Therapeutics
Bluebird Bio
drug pricing
sickle cell disease
Headline: 
U.S. watchdog lifts price estimate for Bluebird, Vertex/CRISPR gene therapies to $2.1 million
snippet: 


The Institute for Clinical and Economic Review, an influential drug pricing watchdog, raised the price estimate of two experimental gene therapies from Vertex Pharmaceuticals/CRISPR Therapeutics and Bluebird Bio.

Do Not Allow Advertisers to Use My Personal information